For 2024, R1 now expects to generate: Revenue of $2.60 billion to $2.64 billion; GAAP operating income of $85 million to $105 million; Adjusted EBITDA of $625 million to $650 million

As part of the partnership, R1 has entered into a definitive agreement to acquire the Acclara business for $675 million in cash and warrants to purchase 12.2 million shares of R1 stock.

R1 expects the acquisition of Acclara, together with the new partnership with Providence, to contribute more than $625 million in revenue and approximately $185 million to Adjusted EBITDA by year five of the partnership, not including potential revenue synergies.

Nov 15, 2024 · R1 RCM, a leader in healthcare revenue cycle management, has entered into a definitive agreement with Raven Acquisition Holdings. Under the terms of the merger, each share of R1 RCM's common stock will be converted into $14.30 in cash.

Aug 2, 2024 · TowerBrook Capital Partners and Clayton, Dubilier & Rice (CD&R), through their affiliated investment funds, are set to acquire healthcare technology company R1 RCM in an all-cash transaction valued at nearly $8.9bn.

Aug 1, 2024 · Kirkland & Ellis advised healthcare services provider R1 RCM Inc. (NASDAQ: RCM) on a definitive agreement to be acquired in an all-cash transaction with an enterprise value of $8.9 billion by investment funds affiliated with investment management firm TowerBrook Capital Partners and private investment firm Clayton, Dubilier & Rice (CD&R).

Aug 6, 2024 · Wolf Popper LLP is investigating claims on behalf of investors in R1 RCM Inc. (NASDAQ: RCM) concerning the acquisition of R1 RCM by its significant shareholder, TowerBrook Capital Partners L.P. Under the terms of the acquisition, R1 RCM shareholders would receive $14.30 per share in cash.

On July 31, 2024, R1 RCM Inc. (R1) announced that they have entered into a definitive agreement pursuant to which investment funds affiliated with TowerBrook Capital Partners and Clayton, Dubilier & Rice will acquire R1, a leading provider of technology-driven solutions that transform the patient experience and financial performance of ...

Sep 7, 2024 · NEW YORK-- (BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of R1 RCM Inc. (NASDAQ: RCM) to investment funds affiliated with TowerBrook...

As of January 2025 R1 RCM has a market cap of HK$47.05 Billion. This makes R1 RCM the world's 2361th most valuable company by market cap according to our data.